The aim of this single-blind cross-over trial was to compare fenclofenac with regard to efficacy and patient preference with soluble aspirin, a drug of proven value in the treatment of rheumatoid arthritis.
Aim
The aim of this single-blind cross-over trial was to compare fenclofenac with regard to efficacy and patient preference with soluble aspirin, a drug of proven value in the treatment of rheumatoid arthritis.
Method
The trial was a cross-over single-blind (the observer) study, each drug being prescribed in random order for consecutive four-week periods (Fig 1) . The daily dose of each drug was of an order expected to exert both an analgesic and an anti-inflammatory effect, 1200 mg fenclofenac and 3600 mg soluble aspirin. Fenclofenac was prescribed as tasteless white 300 mg tablets, 600 mg being taken with breakfast and the evening meal. Soluble aspirin B.P. was prescribed as white scored 300 mg tablets, 900 mg being dissolved in water and taken with breakfast, lunch, tea and the evening meal. All patients gave written informed consent, knowing that both drugs were active, but that one was 'new' and the other had been used for many years in the treatment of rheumatoid arthritis.
Tablets for each treatment period were dispensed by the hospital pharmacist in unlabelled containers, together with the appropriate written instructions; 224 tablets of paracetamol in a labelled container were provided for each treatment period for use as a 'rescue' drug. All unused Assessments were made at base line and at the end of each treatment period or at the time of withdrawal if an adverse effect made it unwise to complete the full four weeks on either drug.
Objective measures comprised duration of morning stiffness, grip strength, proximal interphalangeal joint (PIP) circumference and the number of pain-free joints on active non-weightbearing movement.
Subjective measures comprised overall sense of well-being, amount of pain in the previous two days and observer's assessment of disease activity. Pain at the time of the examination was recorded on a visual analogue scale.
Laboratory measures comprised Hb, WBC, ESR, platelets, Rose-Waaler (RW), latex, Creactive protein (CRP), urea, alkaline phosphatase, SGPT and urinalysis for glucose, protein and blood.
Patients
Eighteen patients entered the trial, 13 women and 5 men. All fulfilled the ARA criteria for definite or classical rheumatoid arthritis (Ropes et al. 1959) and in all the disease activity was such as to call for the use of an anti-inflammatory analgesic drug. The patients' mean age was 55.5 years (range 32-78) and the mean duration of the disease 13.6 years (range 1-33). Patients with known intolerance to soluble aspirin were excluded from the trial, as were those who had been treated with an anti-malarial or immunosuppressive agent, penicillamine or gold salt in the preceeding six months.
In 10 patients the trial drug was the sole antirheumatic agent. Eight patients continued prednisolone in a dose which remained constant throughout the trial and did not exceed a daily total of 7.5 mg. Six patients were taking no other drugs, but the remainder continued with therapy for coincidental maladies (Table 1) . Three patients had mild hypertension, one continuing methyldopa. Two patients had had myxcedema in the past but at the time of the trial were euthyroid and remained on a small maintenance dose of thyroxine. No patients gave a history of allergy to any drug, but one patient had been unable to tolerate indomethacin because of dyspepsia and a second patient had had mild thrombocytopenia during treatment with gold salts 18 months before the trial began.
Results
Nine patients completed the full four weeks on each treatment period, a further 6 sampling both drugs (Fig 2) . Overall, there were trouble-free four-week courses of treatment with each drug. A further patient completed three trouble-free weeks with each drug but he found both drugs less effective than his pre-trial medication and was unwilling to continue longer than three weeks on either. The only major adverse effect encountered in this trial was a rash of sufficient severity for the particular drug to be stopped in 7 of 18 patients.
If this occurred during the first treatment period pre-trial medication was resumed until the rash subsided, then, if the patient agreed, the other trial drug was prescribed.
Objective and subjective measures: No statistically significant difference was found between fenclofenac and soluble aspirin at the end of four weeks' treatment with each drug in any of the parameters measured (Table 2) . Morning stiffness was less and grip strength better after four weeks' treatment with fenclofenac 1200 mg than with soluble aspirin 3600 mg, but these differences did not reach statistical significance. Note also that although the patients recorded little or no pain at the time of the examination (visual analogue) all declared that their pain in the past two days had been slight or moderate, perhaps adding 'my knee has been murder'. This discrepancy doubtless reflects the difference between pain at rest (visual analogue) and pain associated with ordinary activities.
Laboratory measures: No significant change occurred in hematological or serological tests and no biochemical abnormality occurred with the exception of a single raised SGPT in one patient at the end of the fenclofenac treatment period. This patient had had a transiently raised SGPT when treated previously with another phenylacetic acid and this biochemical abnormality is not regarded as significant.
Adverse Effects
Apart from the rashes the trial was remarkably trouble free. All 'complaints' are listed in Table 3 . Five of 17 patients who took fenclofenac developed a rash appearing on Day 11, 12, 15, 24, Table 3 Adverse effects (18 patients Discussion It has become fashionable in some quarters (British Medical Journal 1977) to question the value of acetylsalicylic acid in the treatment of rheumatoid arthritis because of the possibility of gastrointestinal adverse effects, although entericcoated or liquid preparations and other formulations are available as alternatives to the ordinary or soluble 'aspirin'. But the efficacy of aspirin is unquestioned, so when a new non-steroidal antiinflammatory agent has been shown to be active in placebo and open trials the yardstick for efficacy has usually been a comparison with aspirin. Yet the authors know of no such crossover trial in which aspirin was given in the way in which it is actually prescribed for and taken by patients. Thus ordinary acetylsalicylic acid may have been used (a form rarely used in clinical practice) or a calcium acetylsalicylate has been used but encapsulated and swallowed rather than being dissolved in water before ingestion. In the fenclofenac/soluble aspirin trial both drugs were used in exactly the same way as either would be used in the routine treatment of rheumatoid arthritis. Although the tablets were unlabelled patients might have recognized the soluble aspirin tablets, both by taste and by the instruction to dissolve 3 in half a glass of water, taking this medication 4 times daily. The daily treatment with fenclofenac was 4 tablets, 2 swallowed with a drink during breakfast and 2 with the evening meal. Thus only the observer was truly blind. The trial mimicked normal treatment for two consecutive four-week periods. Although this is a short time in terms of treatment of rheumatoid arthritis the authors believe that cross-over trials which provide for less than four weeks' treatment with two active drugs is too short to provide useful information about efficacy, tolerance and early onset adverse effects for the following reasons:
(1) The effect of pre-trial medication, or of the drug taken during the first treatment period may persist for hours or days after the last dose has been absorbed. and 24. The rash was a generalized erythematous eruption, clearing completely within 7-10 days of stopping fenclofenac. In 4 patients pruritus was troublesome and an anti-histamine was required for 3 or 4 days. The 2 rashes which occurred when patients were taking soluble aspirin were localized, developed earlier (on Days 5 and 9) and took longer to clear. One was pruritic and an antihistamine was prescribed.
Patient Preference
Of the 9 patients who completed the trial 5 preferred fenclofenac, one soluble aspirin and 3 expressed no preference (Table 4 ). This result was not statistically significant. However, many patients spontaneously commented that they liked twice daily medication both for convenience and because they liked to take as few tablets as their physician will permit! Unused tablet counts illustrate this preference for twice daily medication: fenclofenac, mean 3.3 tablets returned (i.e. less than one day's treatment); soluble aspirin, mean 37.2 tablets returned (i.e. greater than 3 days' treatment). Paracetamol tablets were available for use as a rescue drug if an additional analgesic was required. During the four weeks on fenclofenac the mean consumption of paracetamol was 45 tablets (11 a week), during the soluble aspirin period 53 tablets (13 a week).
Efficacy
Efficacy was compared to the pre-trial analgesic regime. Fifteen of 17 patients who sampled fenclofenac for periods ranging from 11 to 28 days found it effective, as did 14 of 16 patients who took soluble aspirin for periods of 5-28 days (Table 5 ). One patient found both drugs unhelpful, 2 other patients who each sampled only one drug preferred their original medication. Thus 15 of 18 patients found the trial medication at least as effective as their pre-trial regime and 3 expressed a very strong positive preference for one of the trial drugs which in each case proved to be fenclofenac.
(2) Adverse effects may be related to the duration of therapy and so never occur if the trial period is brief.
(3) When comparing two effective drugs (in contrast to comparing an effective drug with placebo) treatment should last for a minimum of three weeks so as to eliminate the 'placebo' response to inadequate doses of otherwise effective drugs (Katona et al. 1971) .
The present study supports this belief. Had the treatment periods been of two weeks' duration 4 rashes would have developed-2 with each drug. Extension to four-week periods added 3 more rashes, all during treatment with fenclofenac and developing during the third and fourth weeks. Thus the greater propensity of fenclofenac to produce a rash would not have been established had the trial periods been limited to two weeks. The four-week course also gave the 3 patients who strongly preferred fenclofenac sufficient time to be sure of their assessment and to make the authors feel confident that this was a genuine response.
Experience in this trial highlighted the importance of choosing how best to record the effect of a drug on pain. If the visual analogue method alone had been used pain in individual patients would frequently have been recorded as absent or minimal, yet the same patients often assessed the amount of pain that they had had in the previous two days as being moderately severe. An estimate of pain in the last two days cannot meaningfully be quantified on a numerical scale but may provide a more accurate measure of efficacy of treatment in that it has been experienced during normal activities. The aim of this trial was to compare efficacy and patient preference. A comparison of adverse effects was deliberately excluded as patients with known intolerance to soluble aspirin were excluded. Thus the incidence of aspirin-induced adverse effects was almost certainly less than would have been encountered in an unselected population. This caveat does not apply to fenclofenac and it was noticeable that the drug was very well tolerated and that there were remarkably few complaints. However, the incidence of rash was high. Five rashes in 17 patients is at variance with the experience of other workers; thus R B Smith (1977, personal communication) encountered rashes in 56 of 412 patients (13.6%), 34 being withdrawn, but 6 eventually restarted fenclofenac, so that finally all but 6.8 % were able to continue treatment. It is difficult to explain these dif-ferences but in open trial the starting dose was smaller, and, as with many other drugs (Hill 1977) , it may be prudent to achieve the optimum maintenance dose of fenclofenac by regular increments, and by so doing the incidence of rash may fall.
Our patients continued a variety of drugs prescribed for non-rheumatic complaints but no cross-reaction was observed.
It was disappointing that only 9 out of 18 patients completed both four-week periods of treatment. This was in the main due to advetse reactions, there were 5 patients wlithdrawn on fenclofenac, and 4 on soluble aspirin. Only one patient failed to complete the trial primarily for lack of efficacy of both drugs (Fig 2) . Of the 9 who did complete the trial all had eight trouble-free weeks and found both drugs at least as effective as previous treatment. Five of the 9 patients preferred fenclofenac, one soluble aspirin. Five of the 6 patients who sampled both drugs but failed to complete the full treatment periods also found fenclofenac effective, 3 preferring fenclofenac and 2 soluble aspirin. In all there were II trouble-free four-week treatment periods vith each drug. Patients like taking pills only twice a day, finding it easier to remember and feeling less restricted by 'all those tablets', thus removing the temptation to try and cut down on the daily ration. Twice daily medication has a lot to offer, and if the problem of rashes could be overcome then fenclofenac would prove a useful addition to the nonsteroidal anti-inflammatory group of drugs. Summary A daily dose of fenclofenac 1200 mg was compared with soluble aspirin 3600 mg in a singleblind cross-over trial of eight weeks' duration. Of 18 patients, 15 sampled both drugs, 9 completed four weeks' treatment with each preparation. There was no statistically significant difference in objective or subjective measures between fenclofenac and soluble aspirin. Rashes developed in 5 of 17 patients taking fenclofenac and 2 of 16 taking soluble aspirin. Fenclofenac was given twice daily and patients liked this regime.
